Prophylactic Effects of Interleukin-2 Receptor Antagonists against Graft-versus-Host Disease Following Unrelated Donor Peripheral Blood Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 5, 2012, Pages 754-762

  Fang, Jun ^a   Hu, Chenghao ^b   Hong, Mei ^a   Wu, Qiuling ^a   You, Yong ^a   Zhong, Zhaodong ^a   Li, Weiming ^a   Zou, Ping ^a   Hu, Yu ^a   Xia, Linghui ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

Anti CD25 monoclonal antibody; Graft versus host disease; Interleukin 2 receptor antagonists; Peripheral blood stem cell transplantation; Unrelated donor

Indexed keywords

BASILIXIMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DACLIZUMAB; ETOPOSIDE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; INTERLEUKIN 2 RECEPTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BACTERIAL PNEUMONIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CHILD; CHIMERA; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; MYCOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT RESPONSE; UNRELATED DONORS; VIRUS LOAD; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CHINA; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOGLOBULIN G; LEUKEMIA, LYMPHOID; MALE; MIDDLE AGED; NEOPLASM GRADING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; UNRELATED DONORS;

EID: 84859831262     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.09.005     Document Type: Article

References (51)

1. Schlenk R.F., Döhner K., Mack S., et al. Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. J Clin Oncol 2010, 28:4642-4648.
2. Gupta V., Tallman M.S., Weisdorf D.J. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 2011, 117:2307-2318.
3. Basara N., Baurmann H., Kolbe K., et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant 2005, 35:1011-1018.
4. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001, 98:2942-2947.
5. Koreth J., Antin J.H. Current and future approaches for control of graft-versus-host disease. Expert Rev Hematol 2008, 1:111.
6. Bacigalupo A., Lamparelli T., Gualandi F., et al. Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. Biol Blood Marrow Transplant 2002, 8:656-661.
7. Bacigalupo A. Antithymocyte globulin for prevention of graft-versus-host disease. Curr Opin Hematol 2005, 12:457-462.
8. Brennan D.C., Daller J.A., Lake K.D., et al. Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006, 355:1967-1977.
9. Sageshima J., Ciancio G., Chen L., Burke G.W. Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation. Biologics 2009, 3:319-336.
10. Mattei M.F., Redonnet M., Gandjbakhch I., et al. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy. J Heart Lung Transplant 2007, 26:693-699.
11. McKeage K., McCormack P.L. Basiliximab: a review of its use as induction therapy in renal transplantation. BioDrugs 2010, 24:55-76.
12. Yao G., Albon E., Adi Y., et al. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children. Health Technol Assess 2006, 10. iii-iv, ix-xi, 1-157.
13. Chapman T.M., Keating G.M. Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs 2003, 63:2803-2835.
14. Berger M., Biasin E., Saglio F., Fagioli F. Innovative approaches to treat steroid-resistant or steroid refractory GVHD. Bone Marrow Transplant 2008, 42:S101-S105.
15. Depper J.M., Leonard W.J., Robb R.J., Waldmann T.A., Greene W.C. Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J Immunol 1983, 131:690-696.
16. Miano M., Cuzzubbo D., Terranova P., et al. Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience. Bone Marrow Transplant 2009, 43:423-427.
17. Funke V.A., de Medeiros C.R., Setúbal D.C., et al. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplant 2006, 37:961-965.
18. Wawer A., Laws H.J., Dilloo D., Göbel U., Burdach S. Long-time survival after unrelated bone marrow transplantation in children and adolescents and targeted therapy with CD25 blockade to prevent GVHD. Klin Padiatr 2004, 216:169-175.
19. Ji S.Q., Chen H.R., Yan H.M., et al. Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies. Bone Marrow Transplant 2005, 36:349-354.
20. Shamsi T.S., Irfan M., Farzana T., et al. Allogeneic peripheral blood stem cell transplant (PBSCT) using anti-IL2 receptor antibody Daclizumab for the prevention of acute graft versus host disease in steroid refractory Diamond Blackfan anaemia: a case report. J Pak Med Assoc 2005, 55:454-455.
21. Chen H.R., Ji S.Q., Wang H.X., et al. Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion. Exp Hematol 2003, 31:1019-1025.
22. Maschan A.A., Trakhtman P.E., Balashov D.N., et al. Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors. Bone Marrow Transplant 2004, 34:305-307.
23. Shigematsu A., Kondo T., Yamamoto S., et al. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2008, 14:568-575.
24. Kern W., Haferlach T., Schoch C., et al. Early blast clearance by remission induction chemotherapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML cooperative group (AMLCG) 1992 trial. Blood 2003, 101:64-70.
25. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRCAML10 trial-The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
26. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
27. Schoch C., Haferlach T., Haase D., et al. Patients with denovo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. Br J Haematol 2001, 112:118-126.
28. Appelbaum F.R. Who should be transplanted for AML. Leukemia 2001, 15:680-682.
29. Schoch C., Kern W., Schnittger S., Hiddemann W., Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1092 patients with de novo AML. Leukemia 2004, 18:120-125.
30. Greenberg P., Cox C., Le Beau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
31. Antin J.H., Childs R., Filipovich A.H., et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2001, 7:473-485.
32. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
33. Sullivan K.M. Graft-versus-host disease. Hematopoietic Cell Transplantation 1999, 515-536. Blackwell Scientific, London, Oxford. E.D. Thomas, K.G. Blume, S.J. Forman (Eds.).
34. Grewal S.S., Barker J.N., Davies S.M., Wagner J.E. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?. Blood 2003, 101:4233-4244.
35. Duggan P., Booth K., Chaudhry A., et al. Unrelated donor BMT recipients given pretransplant low-dose antithymocyte globulin have outcomes equivalent to matched sibling BMT: a matched pair analysis. Bone Marrow Transplant 2002, 30:681-686.
36. Finke J., Bethge W.A., Schmoor C., et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009, 10:855-864.
37. Seggewiss R., Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010, 115:3861-3868.
38. Campara M., Tzvetanov I.G., Oberholzer J. Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation. Expert Opin Biol Ther 2010, 10:959-969.
39. Couriel D., Caldera H., Champlin R., Komanduri K. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004, 101:1936-1946.
40. Salvana E.M., Salata R.A. Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev 2009, 22:274-290.
41. Pidala J., Tomblyn M., Nishihori T., et al. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011 Jan 6, [Epub ahead of print].
42. Blaise D., Olive D., Michallet M., Marit G., Leblond V., Maraninchi D. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet 1995, 345:1144-1146.
43. Schmidt-Hieber M., Fietz T., Knauf W., et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol 2005, 130:568-574.
44. Lu D.P., Dong L., Wu T., et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006, 107:3065-3073.
45. Kandus A., Arnol M., Omahen K., et al. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study. Transplantation 2010, 89:1022-1027.
46. Naderi G.H., Mehraban D., Ganji M.R., Jafarpouriani M., Latif A.H. The outcome of induction therapy with monoclonal antibodies in kidney transplantation among Iranian patients: a prospective study. Transplant Proc 2009, 41:2768-2771.
47. Vega O., Cárdenas G., Correa-Rotter R., Alberú J., Morales-Buenrostro L.E. Basiliximab vs. limited-dose daclizumab (2 mg/kg) administered in single or two separated doses in kidney transplantation. Rev Invest Clin 2008, 60:82-86.
48. Pham K., Kraft K., Thielke J., et al. Limited-dose Daclizumab versus Basiliximab: a comparison of cost and efficacy in preventing acute rejection. Transplant Proc 2005, 37:899-902.
49. Lin M., Ming A., Zhao M. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study. Clin Transplant 2006, 20:325-329.
50. Hershberger R.E., Starling R.C., Eisen H.J., et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005, 352:2705-2713.
51. Kircher B., Latzer K., Gastl G., Nachbaur D. Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD25 monoclonal antibodies. Clin Exp Immunol 2003, 134:426-430.